烟囱技术与开窗技术腔内修复近肾腹主动脉瘤的单中心对比评估
住院死亡率烟囱组显著更高(16.1% vs 3.3%),但中期生存、再干预及靶血管通畅率无显著差异,开窗组I型内漏免除率更优。
要点
- 烟囱EVAR住院死亡率显著高于开窗EVAR(16.1% vs 3.3%,P=0.03)。
- 开窗EVAR的I型内漏免除率在12和24个月均显著更优(P=0.01)。
- 两组中期生存、再干预及靶血管通畅率无显著差异。
核心结论
- 烟囱EVAR在本系列中显示出有希望且持久的中期结果,与开窗EVAR相比不应视为对立策略而应互补。
研究设计与样本
- 单中心回顾性分析2010年1月至2015年1月前瞻性收集的数据,纳入因合并症过多不适合开放手术的近肾腹主动脉瘤患者。
主要发现
- 烟囱组平均年龄显著更高(开窗组71.3±8.2岁 vs 烟囱组75.3±6.6岁;P=0.02),术前慢性肾病比例显著更高(13例[14.4%] vs 12例[38.7%];P=0.009)。
- 靶血管成功重建率开窗组99.0%(196/198) vs 烟囱组97.4%(38/39)(P=0.3)。
- 住院死亡率烟囱组显著更高(3.3% vs 16.1%;P=0.03),急性肾损伤和慢性肾病发生率两组无显著差异。
- 12和24个月总生存率开窗组91.4% vs 烟囱组82.1%和81.8% vs 69.0%(P=0.4),免于动脉瘤相关再干预率93.3% vs 82.1%和84.9% vs 82.1%(P=0.6),靶血管一期通畅率97.5% vs 89.9%(P=0.06)。
- 开窗EVAR在12和24个月免于I型内漏生存率显著更高(100% vs 89.0%和97.7% vs 89.0%;P=0.01),动脉瘤最大横径缩小两组无显著差异。
临床怎么用
- 烟囱EVAR具有现货可用、通用性强和低Profile器件的潜在优势,可作为开窗EVAR的互补选择。
- 选择烟囱EVAR时需权衡其较高的住院死亡率,并加强围手术期管理。
- 开窗EVAR在减少I型内漏方面表现更优,长期随访中需关注内漏监测。
局限性
- 单中心回顾性研究,样本量有限(烟囱组仅31例),两组基线特征存在显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With approval of on-label fenestrated (F-) endovascular aortic repair (EVAR), concerns regarding long-term patency and endoleaks (ELs) after chimney graft (CG)-EVAR were raised. To add supportive data on the value of this technique, we chose to report the midterm results of CG-EVAR in a single center with standardized methods and to compare them to F-EVAR. METHODS: A retrospective analysis of prospectively gathered data from January 2010 to January 2015 was conducted, and patients with excessive comorbidities for open repair treated by CG-EVAR or F-EVAR were included. RESULTS: Ninety patients were treated by F-EVAR (88 men, 198 targets vessels) and 31 by CG-EVAR (26 men, 39 targets vessels, 12.9% treated in emergency; P = 0.001). Mean age was significantly higher in the CG group (71.3 ± 8.2 years in the FG group vs. 75.3 ± 6.6; P = 0.02), and there were significantly more patients suffering from preoperative chronic kidney disease (CKD) (13 [14.4%] treated by F-EVAR vs. 12 [38.7%]; P = 0.009). Target vessels were successfully reconstructed in 99.0% (196/198 target vessels) vs. 97.4% (38/39 target vessels) of cases (P = 0.3). In-hospital mortality was significantly higher after CG-EVAR (3.3% vs. 16.1%; P = 0.03). Incidence of acute kidney injury and CKD did not differ significantly between both groups. At 12 and 24 months, overall survival was 91.4% after F-EVAR vs. 82.1% and 81.8% vs. 69.0% (P = 0.4), estimated freedom from aneurysm related reintervention was 93.3% vs. 82.1% and 84.9% vs. 82.1% (P = 0.6), and target vessel's primary patency rate was 97.5% vs. 89.9% (P = 0.06), respectively. Freedom from type I EL's survival was significantly higher after F-EVAR at 12 and 24 months (100% vs. 89.0% and 97.7% vs. 89.0%; P = 0.01), but aneurysm maximum transverse diameter decrease did not differ significantly. CONCLUSIONS: There are potential advantages to CG-EVAR with off-the-shelf availability, versatility, and low-profile devices. In this series, patients treated by CG-EVAR showed promising and durable midterm results compared with F-EVAR. CG-EVAR and F-EVAR should not be apprehended as opposed strategies but more as complementary ones, while the best indications for CG-EVAR are clarified.
引用
- Caradu C, Morin J, Poirier M, et al. Monocentric Evaluation of Chimney Versus Fenestrated Endovascular Aortic Repair for Juxtarenal Abdominal Aortic Aneurysm. Ann Vasc Surg. 2017. PMID: 28161566. doi:10.1016/j.avsg.2016.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。